IN2012DN00797A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00797A IN2012DN00797A IN797DEN2012A IN2012DN00797A IN 2012DN00797 A IN2012DN00797 A IN 2012DN00797A IN 797DEN2012 A IN797DEN2012 A IN 797DEN2012A IN 2012DN00797 A IN2012DN00797 A IN 2012DN00797A
- Authority
- IN
- India
- Prior art keywords
- relates
- present
- monoclonal antibody
- antibody
- aureus
- Prior art date
Links
- 101710092462 Alpha-hemolysin Proteins 0.000 abstract 1
- 101710197219 Alpha-toxin Proteins 0.000 abstract 1
- 101710124951 Phospholipase C Proteins 0.000 abstract 1
- 206010000269 abscess Diseases 0.000 abstract 1
- 239000002776 alpha toxin Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09010311A EP2284193A1 (en) | 2009-08-10 | 2009-08-10 | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| US26633009P | 2009-12-03 | 2009-12-03 | |
| PCT/EP2010/004884 WO2011018208A1 (en) | 2009-08-10 | 2010-08-10 | Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00797A true IN2012DN00797A (enExample) | 2015-06-26 |
Family
ID=41381987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN797DEN2012 IN2012DN00797A (enExample) | 2009-08-10 | 2010-08-10 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9249215B2 (enExample) |
| EP (3) | EP2284193A1 (enExample) |
| JP (1) | JP6064241B2 (enExample) |
| KR (1) | KR101836130B1 (enExample) |
| CN (1) | CN102549013B (enExample) |
| CA (1) | CA2769394C (enExample) |
| ES (2) | ES2529175T3 (enExample) |
| IL (1) | IL217746A (enExample) |
| IN (1) | IN2012DN00797A (enExample) |
| RU (1) | RU2529946C9 (enExample) |
| WO (1) | WO2011018208A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013013323A1 (en) * | 2011-07-28 | 2013-01-31 | Cangene Corporation | Staphlococcus aureus alpha-hemolysin antibodies |
| WO2013093693A1 (en) * | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
| CA2870223A1 (en) * | 2012-04-17 | 2013-10-24 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody |
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| BR112015010126B1 (pt) | 2012-11-06 | 2022-11-01 | Medimmune, Llc | Uso de um anticorpo anti-alfa toxina (anti-at) de s. aureus isolado |
| CN104211804A (zh) * | 2014-08-20 | 2014-12-17 | 钱泓 | 一种抗金黄色葡萄球菌多克隆抗体的制备与应用 |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| US20220275088A1 (en) * | 2019-06-14 | 2022-09-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| CN112538112B (zh) | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| CN113444171A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| US20230374114A1 (en) * | 2020-04-16 | 2023-11-23 | Dana-Farber Cancer Institute, Inc. | Coronavirus antibodies and methods of use thereof |
| CN113698478B (zh) * | 2020-05-21 | 2025-11-18 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| CN117106077B (zh) * | 2022-04-28 | 2024-07-16 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2255669A1 (en) * | 1996-05-16 | 1997-11-20 | The Texas A & M University System | Collagen binding protein compositions and methods of use |
| CA2881717C (en) * | 2006-06-06 | 2018-06-12 | Cecilia Anna Wilhelmina Geuijen | Human binding molecules having killing activity against staphylococci and uses thereof |
| CN102743747A (zh) | 2006-06-12 | 2012-10-24 | 葛兰素史密斯克蓝生物品公司 | α-毒素在治疗和预防葡萄球菌感染上的用途 |
| JP5658564B2 (ja) * | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
-
2009
- 2009-08-10 EP EP09010311A patent/EP2284193A1/en not_active Withdrawn
-
2010
- 2010-08-10 IN IN797DEN2012 patent/IN2012DN00797A/en unknown
- 2010-08-10 WO PCT/EP2010/004884 patent/WO2011018208A1/en not_active Ceased
- 2010-08-10 EP EP14195810.8A patent/EP2860191B1/en active Active
- 2010-08-10 JP JP2012524142A patent/JP6064241B2/ja not_active Expired - Fee Related
- 2010-08-10 RU RU2012105045/10A patent/RU2529946C9/ru active
- 2010-08-10 US US13/388,254 patent/US9249215B2/en active Active
- 2010-08-10 CA CA2769394A patent/CA2769394C/en active Active
- 2010-08-10 EP EP10743037.3A patent/EP2464665B1/en active Active
- 2010-08-10 ES ES10743037.3T patent/ES2529175T3/es active Active
- 2010-08-10 KR KR1020127004737A patent/KR101836130B1/ko active Active
- 2010-08-10 ES ES14195810.8T patent/ES2651762T3/es active Active
- 2010-08-10 CN CN201080044958.0A patent/CN102549013B/zh active Active
-
2012
- 2012-01-26 IL IL217746A patent/IL217746A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2769394C (en) | 2019-06-25 |
| IL217746A (en) | 2016-05-31 |
| JP6064241B2 (ja) | 2017-01-25 |
| ES2651762T3 (es) | 2018-01-29 |
| EP2464665B1 (en) | 2014-12-03 |
| EP2860191B1 (en) | 2017-10-11 |
| KR20120047270A (ko) | 2012-05-11 |
| CA2769394A1 (en) | 2011-02-17 |
| RU2529946C2 (ru) | 2014-10-10 |
| JP2013501506A (ja) | 2013-01-17 |
| EP2284193A1 (en) | 2011-02-16 |
| CN102549013A (zh) | 2012-07-04 |
| CN102549013B (zh) | 2015-05-06 |
| RU2012105045A (ru) | 2013-09-20 |
| KR101836130B1 (ko) | 2018-03-08 |
| US20120201829A1 (en) | 2012-08-09 |
| EP2464665A1 (en) | 2012-06-20 |
| ES2529175T3 (es) | 2015-02-17 |
| US9249215B2 (en) | 2016-02-02 |
| IL217746A0 (en) | 2012-03-29 |
| RU2529946C9 (ru) | 2015-03-27 |
| WO2011018208A1 (en) | 2011-02-17 |
| EP2860191A1 (en) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00797A (enExample) | ||
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| MY178926A (en) | Bispecific anti-vegf/anti-ang-2 antibodies | |
| IL214884A (en) | Two-specific, three-valent antibody, pharmaceutical preparations containing it and nucleic acids encoding it | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| WO2010115552A8 (en) | Bispecific anti-erbb-3/anti-c-met antibodies | |
| MX340558B (es) | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. | |
| MY162825A (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
| MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
| MX2010006396A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2010005682A (es) | Anticuerpos bivalentes, biespecificos. | |
| UA100874C2 (en) | Bivalent bispecific antibodies | |
| MX2010005888A (es) | Anticuerpos bivalentes biespecificos. | |
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| IL212633A (en) | A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs | |
| UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
| MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
| UA106529C2 (uk) | Гуманізоване антитіло до cxcr4 для лікування раку | |
| JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
| PH12015501360A1 (en) | Bmp-6 antibodies |